Universität Wien

323105 VU Innovation & Leadership in Preclinical Drug Development - MPS5 (2025S)

2.00 ECTS (1.00 SWS), SPL 32 - Pharmazie
Prüfungsimmanente Lehrveranstaltung
Moodle

Details

Sprache: Englisch

Lehrende

Termine

Monday       03.03. 16:45 - 18:45   
Wednesday   05.03. 16:45 - 18:45 
Thursday  06.03. 16:45 - 18:45   
Tuesday        11.03. 16:45 - 18:45   
Thursday      13.03. 16:45 - 18:45   
Tuesday       18.03. 16:45 - 18:45     
Thursday      20.03. 16:45 - 18:45
Monday      24.03. 16:45 - 18:45 
Tuesday  25.03. 16:45 - 18:45 
Thursday       27.03. 16:45 - 18:45 
Tuesday   01.04. 16:45 - 18:45 
Dienstag       03.04. 16:45 - 19:15 
Freitag 04.04 16:45- 19:15 (coaching sessions-preparation for final evaluation- either on 04.04 or 04.07)
Montag 07.04 16:45- 19:15 (coaching sessions-preparation for final evaluation- either on 04.04 or 04.07)
Donnerstag  * 08.04. 17:00 - 20:00 (Final Evaluation- presence required)

Information

Ziele, Inhalte und Methode der Lehrveranstaltung

This course will introduce the concepts of disruptive innovation, and development of leadership competences in the context of innovation projects. We will review exemplary innovators in the health care and technology sectors, explore leadership concepts involving self-awareness and awareness of others, in order to develop capabilities for creative problem solving, and effective persuasive communication. These competencies are needed to successfully navigate innovation projects and are valuable assets for professional life. Armed with this knowledge, participants will forms teams, identify a challenge related to drug discovery for which they will design an innovative solution and present a pitch to convince others that their idea is worth adopting. The challenge will provide a framework and context to: 1) explore the unique leadership competencies needed to guide and shape creative teams, 2) inspire the imagination needed to formulate and recognize a good idea, and further transform it into an innovation, and 3) develop a strategy to present and communicate effectively and persuasively and 4) increase awareness of innovation opportunities in the healthcare and drug discovery sectors.
This course is in English and fulfills 2 ECTS.
An experiential learning method allows students to apply concepts covered in class to real situations.
- Laptops, tablets, phones or other devices are allowed and encouraged in this class. These tools will enable you to search the internet and gather information for your projects and class discussion.

Art der Leistungskontrolle und erlaubte Hilfsmittel

1. Attendance & Participation: participants are expected to attend all course sessions and actively participate in the course.
2. Three team oral presentations and exercises to be handed in as outlined during the course.
3. Participants will be assessed individually on attendance, application of concepts learned in class, relevant participation in discussions, active and meaningful contribution to team assignments and exercises.

Mindestanforderungen und Beurteilungsmaßstab

-Class attendance.
- Active participation in class and with team.
- Deliver assignments as outlined in class.
- Three (3) oral presentations (team effort).
Final Presentation (3rd)- Final evaluation. Presentation of pitch and early stage solution design concept (team effort).

Prüfungsstoff

Required Final Assignment - Oral presentation with a developed story line (Pitch), and a primitive prototype design (early stage mock-up of the design concept) [team effort]. Presentation to be submitted by email (PPT, KEY or OpenOffice formats) before it is given orally. Content and requirements to be discussed in class.

Literatur

Recommended Reading (optional):
1. Ross, Alec. The Industries of the Future. Simon & Schuster, 2016.
2. Kelley, Tom. The Art of Innovation. New York: Doubleday, 2005.
3. Gallo, Carmine. The Innovation Secrets of Steve Jobs. New York: McGraw-Hill, 2011, 31.
4. Vise, David & Mark Malseed. The Google Story. New York: Dela- corte Press, 2005, 256.
5. John Battelle. The Search: How Google and Its Rivals Rewrote the Rules of Business and Transformed Our Culture. New York: Penguin Group, 2005, 141.
6. Dyer, Jeff, Hal Gregersen & Clayton M. Christiansen. The Innovator’s DNA. Boston, MA: Harvard Business School Press, 2011.
7. Christensen, Clayton M. & Michael Raynor. Innovator’s Solution. Boston, MA: Harvard Business School Press, 2003.
8. Christensen, Clayton M. The Innovator’s Dilemma: When New Technologies Cause Great Firms to Fail. Boston, MA, Harvard Business School Press, 1997.
9. Christensen, Clayton M. Meeting the Challenge of Disruptive Change. Harvard Bus. School Press, 1997.
10. “The Life and Work of Dr. Paul." https://www.janssen.com/belgium/life-and-work-dr-paul
11. Abou-Gharbia, M. & Childers, W.E. Discovery of Innovative Therapeutics: Today's Realities and Tomorrow's Vision. 1. Criticisms Faced by the Pharmaceutical Industry. J. Med. Chem. (2016):56, 5659.
12. Brown, Tim. Design Thinking. Harvard Business Review (2008), 84.

Zuordnung im Vorlesungsverzeichnis

Letzte Änderung: Fr 07.02.2025 05:07